NEXT GENERATION MASS SPECTROMETRY for METABOLITE IDENTIFICATION
NEXT GENERATION MASS SPECTROMETRY for METABOLITE IDENTIFICATION
CAMBRIDGE UK 7 November 2008
Quotient Bioresearch, a leading provider of early phase drug development and sports testing services, today announces that it is investing in its development with the purchase of three Thermo Scientific LTQ Orbitrap™ XL mass spectrometers. This significant investment demonstrates Quotient Bioresearch’s commitment to offering the highest quality service to its customers.
The Thermo Scientific instrumentation will enable Quotient Bioresearch to offer its customers enhanced benefits in mass spectrometry and confirm its position as a leader in drug development and sports testing services. FDA guidance is increasingly driving the need to identify and quantitate key metabolites at the early stage of the drug development process. In recognition of this guidance, Quotient Bioresearch is investing in improved metabolite profiling technology, better coordination of human AME studies, through its radio synthesis group, and an enhanced metabolite identification capability. The decision to invest in three LTQ Orbitrap™ XL mass spectrometers is a key part of Quotient Bioresearch’s drive to develop its metabolite identification services.